Wolwo Pharma(SZ:300357) Xin Lang Zheng Quan·2026-01-12 05:22Core Viewpoint - Iwubio's stock price has shown fluctuations, with a recent decline of 2.05%, while the company has experienced a year-to-date increase of 7.80% in stock value [1] Group 1: Stock Performance - As of January 12, Iwubio's stock price was 30.56 CNY per share, with a market capitalization of 16.001 billion CNY [1] - The stock has seen a 1.56% increase over the last five trading days and a 2.86% increase over the last twenty days, but a decline of 0.78% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, Iwubio reported a revenue of 853 million CNY, reflecting a year-on-year growth of 16.86% [2] - The net profit attributable to shareholders for the same period was 345 million CNY, marking a year-on-year increase of 26.67% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Iwubio was 32,400, a decrease of 6.22% from the previous period [2] - The average number of circulating shares per shareholder increased by 6.63% to 14,927 shares [2] - The company has distributed a total of 9.13 billion CNY in dividends since its A-share listing, with 317 million CNY distributed in the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 5.562 million shares, an increase of 1.4524 million shares from the previous period [3] - New institutional shareholders include Jiashi Huirong Selected Stock A and Penghua Medical Technology Stock A, holding 4.7118 million shares and 4.2986 million shares, respectively [3]